Is Adeshwar Meditex overvalued or undervalued?

As of 7 November 2025, Adeshwar Meditex's valuation grade has moved from expensive to fair, indicating a more favorable assessment of its market position. The company is currently fairly valued, with a PE ratio of 12.77, an EV to EBITDA of 8.25, and a Price to Book Value of 0.71. These figures suggest that the company is trading at reasonable multiples compared to its earnings and asset values.
In comparison to its peers, Adeshwar Meditex stands out as more attractively priced than companies like Poly Medicure, which has a PE ratio of 53.67, and Vimta Labs, with a PE ratio of 47.83. While Adeshwar Meditex has faced challenges in stock performance, particularly with a year-to-date return of -26.04% compared to the Sensex's 6.50%, its current valuation metrics indicate that it is not overvalued, especially in a sector where many peers are significantly more expensive.